Attention!

This page contains information about prescription medications. According to the Russian regulatory requirements, this information can be available only for medical or pharmaceutical stuff.

Do you confirm that you are a medical of pharmaceutical specialist?

Report an adverse reaction
Ru Eng
Main page —
News

News

03/06/2025

GENERIUM initiates clinical trial of original gene therapy drug for Duchenne muscular dystrophy treatment

GENERIUM has received approval to conduct a clinical trial of a gene therapy drug for the treatment of progressive Duchenne muscular dystrophy (DMD).
Ministry of Health of Russia has registered the first biosimilar of ustekinumab – GENERIUM’s drug for the treatment of autoimmune rheumatological diseases 03/03/2025

Ministry of Health of Russia has registered the first biosimilar of ustekinumab – GENERIUM’s drug for the treatment of autoimmune rheumatological diseases

GENERIUM has received marketing authorization1 for its drug "Styleikin"® (INN: ustekinumab), intended for the treatment of plaque psoriasis and psoriatic arthritis in children and adults.
 Izvestia. Local news Overcoming mistrust: SMA patients in Russia have started to receive a domestic drug 02/20/2025

Izvestia. Local news Overcoming mistrust: SMA patients in Russia have started to receive a domestic drug

How the Russian pharma industry overcomes patient mistrust
 GENERIUM has registered the first domestic device for analyzing tuberculosis test results. 01/13/2025

GENERIUM has registered the first domestic device for analyzing tuberculosis test results.

GENERIUM has received a registration certificate for the medical device "SCREENSPOT" - a microplate analyzer for automated reading and analysis of tuberculosis test results based on the ELISPOT method. The equipment is intended for clinical diagnostic laboratories and is capable of enhancing their operational efficiency.
 The Ministry of Health of the Russian Federation has registered the first biosimilar of tocilizumab - a drug from the company GENERIUM. 09/25/2024

The Ministry of Health of the Russian Federation has registered the first biosimilar of tocilizumab - a drug from the company GENERIUM.

The first biosimilar of tocilizumab, developed by Russian scientists and registered by the Ministry of Health of Russia, has been named Complarate©. The drug helps to suppress systemic inflammatory responses and is intended for the treatment of rheumatoid arthritis, including systemic juvenile idiopathic arthritis, therapy for severe conditions related to COVID-19, and life-threatening cytokine release syndrome.
 GENERIUM – the first in Russia to receive a registration certificate for a biomedical cell product 01/19/2024

GENERIUM – the first in Russia to receive a registration certificate for a biomedical cell product

The first advanced therapy medicinal product (ATMP) in Russia was registered by GENERIUM under the trade name EASYTENSE. It is an autologous product based on chondrocytes, the main cells of cartilage tissue, and is intended for the restoration of damage to the cartilage of the knee joint with a defect area of up to 10 square cm.
 GENERIUM has registered a biosimilar of ranibizumab, a medicine for treatment of age-related macular degeneration 12/07/2023

GENERIUM has registered a biosimilar of ranibizumab, a medicine for treatment of age-related macular degeneration

The medicine from GENERIUM under the trade name Laxolan® received a registration certificate from the Ministry of Health. It is intended to treat age-related macular degeneration, as well as certain other retinal diseases that are a common cause of vision loss.
 The first biosimilar of romiplostim has been registered in Russia 10/16/2023

The first biosimilar of romiplostim has been registered in Russia

The first biosimilar of the orphan drug romiplostim has been registered in Russia, which is used as a treatment for immune thrombocytopenia and is included in the List of Vital and Essential Drugs. The registration certificate for the drug "Stimplate" produced by the company "Generium" was issued by the Ministry of Health of Russia.
 Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product 02/09/2022

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product

Third Biosimilar to Reach the Market Under Selexis/Generium Commercial License Agreements
Expo 2020 in Dubai: Russian Pharma Industry Adapts to Pandemic, Open to Cooperation With Arab World 01/28/2022

Expo 2020 in Dubai: Russian Pharma Industry Adapts to Pandemic, Open to Cooperation With Arab World

The 13th meeting of the Russian-Arab Business Council session was held on 25-26 January.
Read more:
Our website uses cookies. You can disable cookie storage in your browser settings. Read more.